Main > PSYCHIATRY > Depression > Treatment > Methylphenidate (CNS Stimulant). > Enantiomer. > (S,S)-Enantiomer. > (L-Threo-Methylphenidate). > Patent > Literature > Claim 1: Dysphoria Treat. Method. > Adm.: L-Threo-Methylphenidate > Purity > 95%. Claim 2: Oral Adm. of > Sufficient Dose such that > First Pass Metabolism is Saturated > resulting in Therapeutically Effect > ive Amount of L-Threo MePhenidate > gets into Systemic Circulation for > desired Effect. Claim 3: > Systemic Adm.: IntraVenous Etc. > Oral Adm.: SubLingual. Claim 6: > Dysphoria Treat. Method: (a) > L-Threo-Methylphenidate (I) Adm. & > (b) Oral Adm. (I) & Conventional

---

(b) Oral Adm. (I) & Conventional's subsections
AntiDepressant. Claim 7: Conv. Anti

(b) Oral Adm. (I) & Conventional's products
This section has no products